News ArticleSai Parenterals Consolidated Revenue Grows 9% to Rs.196 Crore in Q2 FY27; EBITDA Surges 67% with Completion of Key Acquisitions
The company invested Rs.98.8 crore from IPO proceeds in Saicriti Pharma and Prathyak Laboratories and expanded production capacity ahead of FY27 targets
Sai Parenterals Limited posted a consolidated revenue of Rs.196.1 crore for Q2 FY27, a 9% increase quarter-on-quarter, and EBITDA rose 67% to Rs.41.4 crore. The company completed acquisitions of 60% stakes in Saicriti Pharma and Prathyak Laboratories by investing Rs.98.8 crore from IPO proceeds. The new injectable facility at Saicriti Pharma is on track for July 2027, and Unit III expansion increased capacity by 81%. These results are part of the company's transformation and growth strategy for FY27.
Sai Parenterals Limited
General / Other
Sai Parenterals Limited reported a consolidated revenue of Rs.196.1 crore in the quarter ended September 30, 2026, marking a 9% sequential increase and an EBITDA growth of 67% to Rs.41.4 crore. The company completed acquisitions of 60% stakes in Saicriti Pharma and Prathyak Laboratories using Rs.98.8 crore from IPO funds, advancing its pharmaceutical manufacturing and R&D capabilities.
Revenue for the half-year ended September 30, 2026, reached Rs.376 crore, accounting for 50% of the company's full-year revenue target of Rs.750 crore and ahead of its planned 45:55 H1:H2 phasing.
Gross profit rose 26.4% quarter-on-quarter to Rs.93.1 crore with a gross margin increase to 47.5%, attributed to improved inventory management practices and new ERP system implementation.
EBITDA margin improved to 21.1% in Q2 FY27 from 13.7% in Q1 FY27, outpacing the full-year margin guidance of approximately 17%.
Depreciation and amortisation increased to Rs.25.1 crore due to capitalisation related to the Unit III expansion, consolidation of Saicriti Pharma assets, and amortisation of acquired molecules but did not hinder profit growth.
The company completed acquisition of 60% equity stakes in Saicriti Pharma Pvt Ltd and Prathyak Laboratories Pvt Ltd, deploying Rs.98.8 crore in total, with the balance Rs.3 crore reallocated to corporate purposes from planned research center expenditure.
Highlights
- Q2 FY27 consolidated revenue of Rs.196.1 crore, up 9.0% sequentially from Rs.179.9 crore in Q1 FY27.
- Gross profit for Q2 FY27 increased to Rs.93.1 crore with a margin of 47.5%.
- EBITDA rose to Rs.41.4 crore with a 21.1% margin in Q2 FY27, up 67.4% from Q1 FY27.
- Half-year revenue accounts for 50% of the annual target of Rs.750 crore, exceeding planned phasing.
- Rs.98.8 crore from IPO proceeds invested in acquiring 60% stakes in Saicriti Pharma and Prathyak Laboratories.
- New injectable manufacturing facility at Saicriti Pharma is under construction with a July 2027 target for completion, expanding capacity to about 154.66 million units.
Key Data Snapshot
What happened
- Sai Parenterals reported consolidated Q2 FY27 revenue of Rs.196.1 crore, a 9% increase from Q1 FY27, with half-year revenue of Rs.376 crore, achieving 50% of FY27 targets ahead of planned phasing.
- EBITDA for Q2 FY27 rose 67.4% sequentially to Rs.41.4 crore with a margin improvement to 21.1%.
- PAT grew to Rs.10.5 crore in Q2 FY27 despite higher depreciation and amortisation costs.
- The company completed acquisitions of 60% stakes in Saicriti Pharma and Prathyak Laboratories by investing Rs.98.8 crore from IPO proceeds.
Key details
- Gross margin improved to 47.5% in Q2 FY27 driven by tighter inventory management and a new ERP system.
- Depreciation and amortisation rose to Rs.25.1 crore due to asset capitalisation and amortisation of acquired molecules.
- Saicriti Pharma's new critical-care injectable facility construction is ongoing with a targeted completion in July 2027, expected to expand capacity to 154.66 million units.
- The Unit III expansion at Bhongir increased production capacity by 81% to 155 million units per month, with output ramp-up scheduled from Q4 FY27, primarily supporting Australia and New Zealand markets.
- Noumed Pharmaceuticals' contracted Australian OTC supply agreements total AUD 232 million, with production shifting gradually in-house as new facilities commission.
Strategic context
- IPO funds were reallocated but remain focused on expanding EU-GMP compliant injectable capacity and R&D platforms.
- Sai Prathyak Laboratories consolidates group R&D with 28 scientists and a portfolio of 174 molecules and 285 SKUs, expecting to start external CDMO contracts with revenue from FY28.
- The Adelaide facility will commence operations in January 2027 with commercial supply starting April 2027, supporting Noumed Pharmaceuticals' supply chain.
- Portfolio expansion in the Philippines includes addition of 11 molecules and 22 SKUs in cardiovascular therapies during Q2 FY27.
Highlights
- Q2 FY27 consolidated revenue of Rs.196.1 crore, up 9.0% sequentially from Rs.179.9 crore in Q1 FY27.
- Gross profit for Q2 FY27 increased to Rs.93.1 crore with a margin of 47.5%.
- EBITDA rose to Rs.41.4 crore with a 21.1% margin in Q2 FY27, up 67.4% from Q1 FY27.
- Half-year revenue accounts for 50% of the annual target of Rs.750 crore, exceeding planned phasing.
- Rs.98.8 crore from IPO proceeds invested in acquiring 60% stakes in Saicriti Pharma and Prathyak Laboratories.
- New injectable manufacturing facility at Saicriti Pharma is under construction with a July 2027 target for completion, expanding capacity to about 154.66 million units.
Disclosures
- SEBI (LODR) Regulations 2015, Regulation 30(6)
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Muthoot Finance Reports 42% YoY Growth in Consolidated Loan Assets and 39% Rise in Profit After Tax for H1 FY27
Muthoot Finance Limited posted robust unaudited financial results for the half year ended September 30, 2026, with consolidated loan assets under management growing 42% year-on-year to ₹2,09,317 crores and consolidated profit after tax rising 39% year-on-year to ₹6,103 crores.
Read Full Story
Coal India Limited Publishes Tax Notification for 2nd Interim Dividend of FY 2026-27 in Major Newspapers
Coal India Limited has publicly disclosed information regarding the tax on its 2nd interim dividend for the financial year 2026-27 through publications in prominent newspapers Hindu Business Line and Bartaman.
Read Full Story
GAIL India Limited Reports ₹45,924 crore Revenue and ₹4,650 crore PAT in Q2 FY2026-27 Amid Rising Gas Volumes
GAIL (India) Limited posted standalone revenue from operations of ₹45,924 crore and profit after tax of ₹4,650 crore for the second quarter of fiscal year 2026-27, reflecting growth supported by strong natural gas transmission and marketing volumes.
Read Full Story
